Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA testing. In order to conserve the remaining reagent, a controlled process of batch testing was implemented. Therefore, you will likely see additional delays in receiving these supplemental test results.
Read about our plan to mitigate this on the Communications page by clicking this link: Communications
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...